Summary: MAPS Founder and Executive Director Rick Doblin, Ph.D., speaks with Arvind Gupta on IndieBio’s Designing Science podcast about the inception of MAPS, the 30-plus year journey to get MDMA-assisted psychotherapy for PTSD to Phase 3 clinical trials, the current psychedelic movement, and the future of psychedelic research.
Originally appearing here.
Rick Doblin, Founder and Executive Director of Multidisciplinary Association for Psychedelic Studies (MAPS) featured on “Designing Science” podcast with Arvind Gupta, Founder and Managing director of IndieBio.
IndieBio is a leading seed-stage life science accelerator program devoted to funding and building startups dedicated to solving humanity’s most pressing problems through biology.
We enable the best scientists to become entrepreneurs, and nurture the future leaders of movements and systemic change. Our technology focus is on reinventing the food and water supply chain, medicine, healthcare, diagnostics, agriculture, and biomaterial industries. To date, 94 companies have graduated from the program, with a combined current valuation of over $1B.
IndieBio is a member of SOSV a $550M global fund focused on lasting impact.